Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Kallesh D. Jayappa(Carter Center), Michael J. Weber(Carter Center), Timothy P. Bender(Carter Center), Stefan Bekiranov, Vicki L. Gordon, Rosa I. Gallagher(George Mason University), Brian J. Capaldo(University of Virginia), Michael E. Williams(University of Virginia), Craig A. Portell(University of Virginia), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Julia Wulfkuhle(University of California, San Francisco)
Cited by 0
Related Papers
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Antiapoptotic Signalling by the Insulin-Like Growth Factor I Receptor, Phosphatidylinositol 3-Kinase, and Akt
|Molecular and Cellular Biology|1997|1.1k
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
|Blood|2015|408
Androgen Receptor Phosphorylation
|Journal of Biological Chemistry|2002|353